KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Change in Accured Expenses (2018 - 2021)

BioNTech SE (BNTX) posted Change in Accured Expenses of $844365.3 for Q1 2021, up 91.22% on a QoQ basis from $441575.6 in Q1 2020, and up 91.22% year-over-year from $441575.6 in Q1 2020.

BioNTech SE (BNTX) has 4 years of Change in Accured Expenses data on file, last reported at $844365.3 in Q1 2021.

  • In Q1 2021, Change in Accured Expenses rose 91.22% year-over-year to $844365.3; the TTM figure through Mar 2021 stood at -$1.6 million (changed N/A YoY), while the FY2020 annual figure was $2388.2, up 25.66% from the prior year.
  • Change in Accured Expenses rose to $844365.3 in Q1 2021, from $441575.6 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $844365.3 in Q1 2021 and bottomed at -$1.5 million in Q4 2018.
  • A 4-year average of -$402109.9 and a median of -$488330.4 in 2020 frame the typical range for Change in Accured Expenses.
  • Annual changes were most pronounced in 2019 — Change in Accured Expenses increased 3.92% — and 2021, when it jumped 91.22%.
  • Year by year, Change in Accured Expenses stood at -$1.5 million in 2018, then grew by 3.92% to -$1.4 million in 2019, then surged by 131.14% to $441575.6 in 2020, then jumped by 91.22% to $844365.3 in 2021.
  • The last three Change in Accured Expenses figures came in at $844365.3 (Q1 2021), $441575.6 (Q1 2020), and -$1.4 million (Q4 2019), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 931,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 70.50 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 107.70 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -176.03 Mn
10 BioNTech SE 27.66 Bn 7.53 Bn 668.28 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2021 844,365.28
Mar 31, 2021 844,365.28
Mar 31, 2020 441,575.61
Mar 31, 2020 441,575.61
Dec 31, 2019 -1.42 Mn
Dec 31, 2019 -1.42 Mn
Dec 31, 2018 -1.48 Mn
Dec 31, 2018 -1.48 Mn